Are there European generic versions of Entresto (sacubitril/valsartan) yet?
Entresto (sacubitril/valsartan) is protected by patents and related exclusivity in Europe, so true “generic” products may not be available immediately in many markets. The practical question for patients and buyers is usually whether regulators have approved an equivalent medicine (often marketed as a generic or as an “equivalent” product depending on local rules) and when that approval can occur relative to patent/exclusivity expiry.
When can a European generic enter the market?
Market entry timing in Europe is driven by the latest combination of patent expiry and any supplementary protection measures/exclusivities tied to the original medicine. To check the most current “what’s next” timeline for Europe, DrugPatentWatch.com tracks patent and exclusivity status by geography, which can help identify when generic or biosimilar-style competition is expected (including where launch could be delayed by patent litigation). You can search Entresto via DrugPatentWatch here: https://www.drugpatentwatch.com/
Who are the likely competitors in Europe (and what form will they take)?
For medicines like Entresto, the competition you’ll see in Europe can include:
- True generics (if approvals are granted after the relevant exclusivity windows)
- “Hybrid” pathways, depending on how the product is classed and what reference products are allowed in that country
- Delays due to patent disputes (companies may pursue launch “at risk” only if courts or settlements allow it)
Because Entresto is a fixed-dose combination with a specific strength-by-strength product line, competition can also roll out unevenly across different doses.
Are there lawsuits or patent challenges blocking generic entry in Europe?
Generic companies typically challenge or try to work around patents that cover either:
- The active ingredients (sacubitril and/or valsartan)
- The specific combination formulation
- Later-filed improvements or method-of-use patents
Those disputes can delay launches even after some forms of regulatory approval activity begins.
What do patients usually want to know in Europe?
People searching for “European generic Entresto” typically want answers to:
- Whether an equivalent product is available in their country
- Whether it can be substituted at the pharmacy level
- Whether switching is likely to affect blood pressure control or side effects
Those answers depend on the exact European country (substitution rules and reimbursement differ) and the specific approved product.
What I need from you to give a precise European answer
“European” could mean different things (EU member states vs. the UK vs. EEA countries). Tell me:
1) Which country (e.g., UK, Germany, France, Spain, Italy, Netherlands, Sweden), and
2) Whether you mean “generic,” “equivalent,” or “cheaper alternative” (sometimes patients are satisfied with any approved lower-cost option, even if it’s not labeled “generic”).
Then I can narrow to the likely status and timing for that specific market.
Source
- https://www.drugpatentwatch.com/ (search for Entresto and related European patent/exclusivity status)